{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-24-000116","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.431285+00:00","generated_at":"2026-06-03T03:46:10.516444+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine Q1: INGREZZA sales $506M (+23% YoY); GAAP EPS $0.42, non-GAAP EPS $1.20","bullets":["INGREZZA net product sales $506M in Q1 2024 vs $411M in Q1 2023, up 23% year-over-year.","GAAP net income $43.4M ($0.42 diluted EPS) vs net loss $76.6M ($0.79 loss) in Q1 2023.","Non-GAAP net income $124.8M ($1.20 diluted EPS) vs net loss $49.5M ($0.51 loss) a year ago.","Total revenues $515.3M (+23% YoY); cash & equivalents $1.91B at quarter end.","FDA approved INGREZZA SPRINKLE; NDAs submitted for crinecerfont in congenital adrenal hyperplasia."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-24-000116","json":"https://secwatch.observer/filing/0000914475-24-000116.json","markdown":"https://secwatch.observer/filing/0000914475-24-000116.md","text":"https://secwatch.observer/filing/0000914475-24-000116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000116/0000914475-24-000116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000116/nbix-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:46:10.516444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"45088c1280115973dfb812295130ce4094d72e8c","claim":"NEUROCRINE BIOSCIENCES INC reported the first quarter ended March 31, 2024 results: revenue $515.3 million, net income $43.4 million, EPS $0.42. Guidance reaffirmed.","evidence_excerpt":"Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000116/0000914475-24-000116-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$515.3 million"},{"label":"Net income","value":"$43.4 million"},{"label":"EPS","value":"$0.42"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}